anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Proton magnetic resonance spectroscopy (1H-MRS) allows measuring specific brain metabolic alterations in Huntington's disease (HD), and these metabolite profiles may serve as non-invasive biomarkers associated with disease progression. Despite this potential, previous findings are inconsistent. Accordingly, we performed a meta-analysis on available in vivo1H-MRS studies in premanifest (Pre-HD) and symptomatic HD stages (Symp-HD), and quantified neurometabolic changes relative to controls in 9 Pre-HD studies (227 controls and 188 mutation carriers) and 14 Symp-HD studies (326 controls and 306 patients). Our results indicated decreased N-acetylaspartate and creatine in the basal ganglia in both Pre-HD and Symp-HD. The overall level of myo-inositol was decreased in Pre-HD while increased in Symp-HD. Besides, Symp-HD patients showed more severe metabolism disruption than Pre-HD patients. Taken together, 1H-MRS is important for elucidating progressive metabolite changes from Pre-HD to clinical conversion; N-acetylaspartate and creatine in the basal ganglia are already sensitive at the preclinical stage and are promising biomarkers for tracking disease progression; overall myo-inositol is a possible characteristic metabolite for distinguishing HD stages.
OBJECTIVE: Research provides support for the associated risk of inadequate sleep duration, limited physical activity, and excessive media use in attention-deficit/hyperactivity disorder (ADHD) and obesity. The present study aims to (1) examine the association between ADHD and overweight or obese status (OW/OB); (2) comprehensively examine sleep duration, physical activity, and media use as potential moderators of OW/OB; and (3) examine the moderating effects of these health behaviors cross-sectionally by comparing medicated youth with ADHD, unmedicated youth with ADHD, and youth without ADHD.
METHODS: Data were acquired from the 2018 and 2019 National Survey of Children's Health, a nationally representative survey of caregivers conducted across the United States. The current study used data for youth 11-17 years old with a final sample size of 26,644. Hours of sleep, physical activity, and media use per day were dichotomized based on national recommendation guidelines for each health behavior (i.e., either meeting or not meeting guidelines).
RESULTS: The OW/OB prevalence rate was 7% greater among unmedicated youth with ADHD than among medicated youth with ADHD. Medicated youth with ADHD and peers without ADHD had similar OW/OB rates. Among medicated youth with ADHD, physical activity, sleep duration, and media use did not contribute to OW/OB risk after controlling for family poverty level. However, among unmedicated youth with ADHD, meeting sleep duration guidelines was linked to a lower OW/OB risk.
CONCLUSION: Overall, findings suggest that clinical providers and parents may wish to prioritize improved sleep duration in the management of OW/OB risk in youth with ADHD.
Methylphenidate transdermal system has a high potential for abuse and misuse. The use of methylphenidate transdermal system exposes individuals to the risks of abuse and misuse, which can lead to the development of a substance use disorder, including addiction. Methylphenidate can be diverted for non-medical use into illicit channels or distribution [see Drug Abuse and Dependence (9.2)]. Misuse and abuse of CNS stimulants, including methylphenidate transdermal system, can result in overdose and death [see Overdosage (10)], and this risk is increased with higher doses or unapproved methods of administration, such as snorting or injection.

Before prescribing methylphenidate transdermal system, assess each patient’s risk for abuse, misuse, and addiction. Educate patients and their caregivers or families about these risks. Advise patients to store methylphenidate transdermal system in a safe place, preferably locked, and instruct patients to not give methylphenidate transdermal system to anyone else. Throughout methylphenidate transdermal system treatment, reassess each patient’s risk of abuse, misuse, and addiction and frequently monitor for signs and symptoms of abuse, misuse, and addiction.

Methylphenidate transdermal system has special disposal instructions. Instruct patients to find a take back location to dispose of unused or expired methylphenidate transdermal system. If a take back program is unavailable, instruct them to:

1.
     Remove methylphenidate transdermal system from its pouch, separate it from its liner, fold it in half with the adhesive sides touching each other, and immediately flush the used transdermal system down the toilet, and
2.
     Place the pouch and liner in a container, close the container, and throw out the container in the trash (advise patients not to flush the pouch and liner down the toilet).
Prevalent Cohort B will comprise eligible participants with HAE type I or II who have been treated with lanadelumab for \<12 months (i.e., the subset of participants from Prevalent Cohort A who initiated treatment with lanadelumab within \<12 months). The total follow-up encompasses a 12-month pre-treatment and an up to 24-month post-treatment period, as well as a prospective data collection period of participant-specific duration.
Many different non-pharmacological methods are used to cope with negative situations such as pain, fear and anxiety caused by invasive procedures in children. One of these non-pharmacological methods is the distraction. The American Pain Society recommends the use of distraction for pain control in children. With the distraction method, the child's pain is controlled and reduced by focusing the child's attention in another direction. Video games, virtual reality glasses, listening to music, watching cartoons, blowing balloons, reading books, playing with puppet/finger puppets are used as distraction methods. The aim of this study is to determine the effect of distraction method applied with finger puppet on the child's pain level and emotional indicators in children aged 3-6 years who applied to the pediatric emergency department and underwent venous blood collection. The sample size of the study has been determined by the power analysis (G\*Power 3.1.9.2), in line with the results obtained from the studies which have been conducted using a similar research method. The sample size was found to be a total of 76 children including minimum of 38 children for each group. It was estimated that case losses may occur and therefore, it was decided to conduct the study with a total of 80 children including 40 children in two groups. Information Form, Face, Legs, Activity, Cry, Consolability (FLACC) Scale, and Children's Emotional Manifestation Scale will use for data collection. Children and their parents who applied to the pediatric emergency unit will inform about the study. Information about children and their parents included in the study will ask by the researcher through face-to-face interviews and these data will record in 'Information Form' five minutes before the procedure. One minute before the procedure children in the experimental group will start to play with finger puppets under the direction of the researcher. The researcher will continue to distract the child's attention during the procedure with finger puppets. For distraction the researcher will put finger puppets consisting of various animal figures on his finger, and will ask the child to imitate these sounds by making animal-specific sounds that he moves with his finger. The researcher will also draw the child's attention to finger puppets by using methods such as making animals talk to each other and singing. Children in the control group will be given routine practices and no distraction method will be applied. Before and during venipuncture children's pain will evaluate with the FLACC Scale and their emotional status will evaluate with the Children's Emotional Manifestation Scale by the healthcare provider who performs the venipuncture procedure.
ECT will be performed directly after the intratumorally administration of cysplatin (0,5-2 mg/cm3 tumor). CliniporatorTM (IGEA S.P.A., Carpi, Italy) will be used to apply the pulses (8 pulses, 1300 V/cm, 100 μs, 5 kHz). Triggering of the electrical pulses will be synchronized with ECG signals, through the ECG triggering device AccuSync to avoid delivery of pulses in vulnerable period of the heart. The type of electrode used will be selected according to the size and location of the tumors.
The peripheral and bone marrow T cell and mono nucleated cell chimerism will be closely followed-up. In case of decreasing donor chimerism, patients will receive low-dose decitabine with 5mg/m2 daily for 5 days every 6-8 weeks until the chimerism recovered to full donor type (\>98%).
Cardiac remodelling is often most profound in male athletes and in athletes with the greatest volumes of endurance training and is characterized by chamber enlargement and a mild-to-modest hypertrophy. The diastolic filling of the left ventricle (LV) is a complex process including the early recoil of the contracted LV, the active relaxation of the myocardium, the compliance of the myocardium, the filling pressures, and heart rate. Echocardiography is the cornerstone for the clinical assessment of LV diastolic function. LV diastolic function is usually enhanced in elite endurance athletes characterized by improved early filling of the ventricle, while it is preserved or enhanced in other athletes associated with the type of training being performed. This allows for the high performance of any endurance athlete. Typical findings when using resting echocardiography for the assessment of LV diastolic function in endurance athletes include a dilated LV with normal or mildly reduced LV ejection fraction (EF), significantly enlarged left atrium (LA) beyond the commonly used cut-off of 34 mL/m2, and a significantly elevated E/A ratio. The early-diastolic mitral annular velocity and the E-wave peak velocity are usually normal. Importantly, interpretation of the echocardiographic indices of LV diastolic function should always consider the clinical context and other parameters of systolic and diastolic functions. In the absence of an underlying pathology, single measurements outside the expected range for similar athletes will often not represent the pathology.
The Bausch + Lomb Vision Shaping Treatment VST is based on a reverse geometry orthokeratology design that includes a base curve/treatment curve, a reverse curve, alignment curves and peripheral curves. The base curve is used to only flatten the cornea and is not considered a fitting curve. The parameters of the Arise Orthokeratology Lens are controlled to be within the bounds determined by the spherical posterior curves of other lens designs prescribed for the Bausch + Lomb Vision Shaping Treatment. The term peripheral curves excludes the base curve and includes the zones defined as the reverse curve, alignment curves and peripheral curves. Peripheral curves are designed to help control centration of the lens. When there are elevation differences between the flat and steep meridians on the cornea (e.g., corneal toricity), spherical peripheral curves, including the reverse curve, alignment curves and peripheral curves, may not align completely to the cornea and can result in a lens with sub-optimal centration. Aspheric curves and toric (e.g., dual axis) peripheral curves on reverse geometry lenses for overnight orthokeratology have been available in the US market for more than 10 years for fitting lenses. The intent of the Arise Orthokeratology Lens is to provide a stable and centered lens that helps ensure the treatment zone of the lens is well positioned in relation to the pupil and is shaping the central portion of the cornea for optimal results.
Participants in this group will receive standard education on the importance of physical activity in the recovery from cancer and how to become more active. Participants assigned to this group will have the option to participate in the exercise program after the 16-week follow-up assessment.
<P>PROBLEM TO BE SOLVED: To provide a surely ignitable incense stick bundle in response to demand.  <P>SOLUTION: This incense stick bundle 1 is obtained by bundling a plurality of incense sticks 2 and 2a with strips 3 of paper. The incense sticks 2 in the incense sticks 2 and 2a are arranged in the peripheral edge in the radial direction of the incense stick bundle 1 and the incense sticks 2a shorter than the incense sticks 2 are arranged in the central part in the radial direction of the incense stick bundle 1. Each lower end of the incense sticks 2 and 2a is arranged to form a bundle end face 5 on the lower side. A depressed part 6 depressed in the direction C of the bundle center C is formed in the central part in the radial direction of the bundle end face 4 on the upper side of the incense stick bundle 1 by the arrangement of the incense sticks. In this case, the depressed part 6 has a prescribed spatial shape which is a nearly cylindrical form and the caliber M and the depth L are prescribed dimensions. The prescribed shape and dimensions of the recessed part 6 are the shape and dimensions for housing a commercially available candle body 9 composed of a wax part 7 and a wick part 8 inserted into the wax part 7.  <P>COPYRIGHT: (C)2004,JPO
PURPOSE:To provide a remedy for hyperammonemia containing biotin as an active component and effective in lowering the ammonia level in blood and ameliorating hepatic coma. CONSTITUTION:The objective remedy can be prepared by mixing the biotin of formula with conventional drug carrier, dissolution assistant, stabilizing agent, distilled water for injection, etc., and forming to a drug preparation by conventional method. It can be used in the form of tablet, capsule, syrup, injection, etc. Biotin is administered at a rate of 0.5-100mg daily for adult in 1-2 divided doses in the case of injection or in several divided doses in the case of oral drug. Biotin of formula is a white crystal or crystalline powder free from taste and odor. It has a melting point of about 231 deg.C and is little soluble in glacial acetic acid, scarcely soluble in water, ethanol and n-butanol and almost insoluble in ether and chloroform. It is soluble in sodium hydroxide reagent.
The present invention discloses a method for making a chafing dish of a black rooster. The technical procedures are as following: step 1, the negative catalysis of the black rooster is carried out under the room temperature from 20 DEG C to 25 DEG C; step 2, internal organs and buttocks of the black rooster after negative catalysis are thoroughly cleaned after treatment; step 3, the black rooster is soaked for 1 to 2 hours in water from 20 DEG C to 25 DEG C, and welsh onions from 30 to 50 grams, ginger slices from 30 to 50 grams and yellow rice wine from 10 to 20 grams are simultaneously added; step 4, the soaked black rooster is placed into a pot with the boiling water from 90 DEG C to 100 DEG C and is scalded for 5 to 8 minutes; step 5, the scaled black rooster is placed into an old soup pot from 2 to 3 kilograms, seasoning is simultaneously added, and the black rooster is stewed for 20 to 30 minutes. The present invention uses the old soup for stewing the black rooster which is delicious with a fresh taste. The traditional Chinese medicinal material with the nutrient healthcare function is added in the stewing process for the nourishing effect to the body. The present invention is helpful for human body's health and enables the diet to be scientific. The present invention has the advantages of simple manufacture technology, low cost and eating convenience.
Cardiac channelopathies are a group of inherited syndromes that can cause malignant arrhythmias and sudden cardiac death, particularly in the pediatric population. Today, a 12-lead electrocardiogram is the most effective tool to diagnose these diseases. Incomplete penetrance and variable expressivity are hallmarks of these syndromes. Some of these malignant entities may remain hidden and only a trigger such as exercise, emotions or fever can unmask the electrical pattern to diagnose the disease. Sudden cardiac death may be the first manifestation of any of these syndromes. The use of complementary tests that allow early diagnosis is strongly recommended, among which we find: pharmacological provocations, exercise tests, and genetic analysis. Genetic testing makes it possible to unravel the origin of the disease, and also identify family members who carry the harmful genetic defect and are therefore at risk. One of the main challenges in this area is the large number of genetic variants of uncertain significance, which prevent effective translation into clinical practice. Early identification of the pediatric population at risk and adequate risk stratification are crucial to adopting personalized preventive measures that reduce the risk of lethal episodes in this population. What is Known: • In the pediatric population, malignant arrhythmias leading to sudden cardiac death are mainly caused by inherited syndromes. • A conclusive genetic diagnosis unravels the origin of the syndrome and allows cascade screening to identify relatives carrying the genetic alteration. What is New: • The use of sequencing technologies allows a broad genetic analysis, helping to unravel new genetic alterations causing inherited arrhythmogenic syndromes. • A periodic reanalysis of genetic variants that currently have an ambiguous role will help discern those that are truly pathogenic.
Acute phase proteins involved in chronic inflammatory diseases have not been systematically analyzed. Here, global proteome profiling of serum and urine revealed that orosomucoid-2 (ORM2), an acute phase reactant, was differentially expressed in rheumatoid arthritis (RA) patients and showed the highest fold change. Therefore, we questioned the extent to which ORM2, which is produced mainly in the liver, actively participates in rheumatoid inflammation. Surprisingly, ORM2 expression was upregulated in the synovial fluids and synovial membranes of RA patients. The major cell types producing ORM2 were synovial macrophages and fibroblast-like synoviocytes (FLSs) from RA patients. Recombinant ORM2 robustly increased IL-6, TNF-α, CXCL8 (IL-8), and CCL2 production by RA macrophages and FLSs via the NF-κB and p38 MAPK pathways. Interestingly, glycophorin C, a membrane protein for determining erythrocyte shape, was the receptor for ORM2. Intra-articular injection of ORM2 increased the severity of arthritis in mice and accelerated the infiltration of macrophages into the affected joints. Moreover, circulating ORM2 levels correlated with RA activity and radiographic progression. In conclusion, the acute phase protein ORM2 can directly increase the production of proinflammatory mediators and promote chronic arthritis in mice, suggesting that ORM2 could be a new therapeutic target for RA.
Amino acid salts of glutathione are prepared by mixing glutathione and a basic amino acid having two amino groups and one carboxyl group in water or an aqueous solvent and isolating the formed salt.  The preparations of the L-lysine and L-ornithine salts of the reduced form of glutathione, and of the mono- and di-L-ornithine salts of the oxidized form of glutathione are described.  Other specified amino acids are e -aminocaproic acid, L-tryptophan and DL-citrulline.ALSO:Pharmaceutical compositions comprise glutathione, either in its reduced or oxidised form, and one or more compounds selected from basic amino acids having two amino groups and one carboxyl group, mineral acid salts of such basic amino acids, tryptophan, citrulline, and o -amino acids having 3 to 7 C atoms. Specified basic amino acids are ornithine and lysine.  e -aminocaproic acid is exemplified as a o -amino acid.  Either L or DL forms of the amino acids may be used.  The compositions may be administered orally or parenterally.  The invention also comprises salts of glutathione and a basic amino acid having two amino groups and one carboxyl group in suitable pharmaceutical forms, e.g. tablets, capsules, injectable preparations.  The compositions may be used as growth stimulants for domestic animals as well as radiation protectants.
PURPOSE:To A cell activating substance composed of a water-soluble ingredient, extracted from Sophora angustifolia Sieb. et Zucc. of a leguminous plant and having a specific molecular weight. CONSTITUTION:Water in an amount of 5-10 times based on Sophora anguetifolia Sieb. et Zucc. is added thereto and the Sophora angustifolia Sieb. et Zucc. is dipped therein at 4 deg.C for several days while being occasionally stirred. A filtrate is then collected by filtration and concentrated until the volume attains (1/10) to (1/20) under reduced pressure. An organic solvent is added to the resultant concentrate so as to provide about 60% concentration thereof. Centrifugation is carried out to collect precipitates, which are then dissolved in water to perform gel filtration using a column (25X60cm) filled with, e.g. Sephadex G-25(R) and afford a fraction eluting at a specified Kav value, e.g. 0.65-0.86. The resultant fraction is subsequently freeze-dried to provide a cell activating substance having 700-1100 molecular weight. The obtained substance can be used as a promoter for tissue culture or regeneration and treatment of ulcerated and traumatic parts.
Study medication begins in subjects randomized to preoperative DCA. All subjects will be given the 12.5 mg/kg/12 hour DCA for pre-surgical dosing. Post-surgery the GSTZ1 haplotype will be utilized to dose all patients.
Agricultural areas can provide sources of food and hiding and nesting places for wild birds. Thus, the chemical load of potentially toxic elements (Cd, Cu, Pb) due to industrial and agricultural activities can affect not only the adult birds but also the embryos developing in the egg. The toxic effects of heavy metals applied alone were investigated on chicken embryos in the early and late stages of embryonic development using injection and immersion treatment methods. On day 3 of incubation, permanent preparations were made from the embryos to study the early development stage. There were no significant differences observed in embryo deaths and developmental abnormalities in this stage. On day 19 of incubation, the number of embryonic deaths, the body weight of the embryos, and the type of developmental abnormalities were examined. The embryonic mortality was statistically higher in the groups treated with cadmium and lead in the case of the injection treatment. A significant increase in developmental disorders was observed in the copper-treated group using the immersion application. The body weight significantly decreased in the cadmium- and lead-treated group using both treatment methods. However, a significant change in the body weight in the copper-treated group was only realized due to the injection method.
Coronavirus disease 2019 (COVID-19) was an epidemic that effected human health caused by SARS-CoV-2 infection. All-trans retinoic acid (ATRA) has anti-inflammatory capability. In this article, we evaluated the effectiveness and revealed the molecular mechanism of ATRA for treating SARS-CoV-2 using deep learning, in vitro studies, multi-scale molecular modeling, and network pharmacology. The DeepDTA model suggested that ATRA would be effective against COVID-19. In vitro studies confirmed the antiviral activity of ATRA. Subsequently, multi-scale molecular modeling indicated that ATRA could binding to angiotensin converting enzyme 2 (ACE2), 3C-like protease (3CLpro), RNA dependent RNA polymerase (RdRp), helicase, and 3'-to-5' exonuclease by non-covalent interactions. Additionally, network pharmacology suggested that ATRA alleviated inflammatory response by regulating the IL-17 signaling pathway and binding with TNF, PTGS2, and MAPK1 directly. In summary, our findings provide the first evidence that ATRA suppresses the entry and replication of SARS-CoV-2, and regulates inflammatory response of host cells.